Evidence map›Paper›PMID 30524488›Full record

ArticleNeuro-ophthalmology (Aeolus Press)2018

The Pulfrich Phenomenon: Practical Implications of the Assessment of Cases and Effectiveness of Treatment.

Jane Farr, Emily McGarva, Jenny Nij Bijvank, Hans van Vliet, Hinke Marijke Jellema, Michael D Crossland, Axel Petzold

Open access · bronzeAbstract read
In one paragraph

Article in Neuro-ophthalmology (Aeolus Press), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Jane FarrDepartment of Neuro-ophthalmology, Moorfields Eye Hospital, London, United Kingdom.
Emily McGarvaDepartment of Neuro-ophthalmology, Moorfields Eye Hospital, London, United Kingdom.
Jenny Nij BijvankDepartments of Neurology and Ophthalmology, The Dutch Expertise Center for Neuro-ophthalmology, VU University Medical Center, Amsterdam, The Netherlands.
Hans van VlietDepartment of Ophthalmology, Academic Medical Center, Amsterdam, The Netherlands.
Hinke Marijke JellemaDepartment of Ophthalmology, Academic Medical Center, Amsterdam, The Netherlands.
Michael D CrosslandDepartment of Neuro-ophthalmology, Moorfields Eye Hospital, London, United Kingdom.
Axel PetzoldDepartment of Neuro-ophthalmology, Moorfields Eye Hospital, London, United Kingdom.ORCID 0000-0002-0344-9749
Moorfields Eye Hospital · GBAmsterdam UMC Location University of Amsterdam · NLAmsterdam UMC Location Vrije Universiteit Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Pulfrich phenomenon, originally described in normal observers, is a treatable disorder of the perception of movement in depth in cases of unilateral or asymmetric optic neuropathy. Treatment is highly bespoke and factors influencing treatment response and failure remain unclear. We assessed 25 adults with suspected Pulfrich phenomenon due to a range of conditions in two tertiary referral centres. Monocularly tinted spectacles were successful in reducing symptoms of the Pulfrich phenomenon under daylight conditions in nine subjects, eight of whom had optic neuritis. These spectacles were not effective at night and in patients with visual field defects due to ischaemic optic neuropathy, glaucoma, optic disc drusen or severe peripapillary retinal nerve fibre loss on optical coherence tomography.

Indexed as

depth perceptionoptic neuritisPulfrichVisual illusionsvisual rehabilitation

Identifiers

PMID30524488
PMCPMC6276950
OpenAlexW2800952886

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.